A phase II study of neoadjuvant atezolizumab and nab-paclitaxel in patients with anthracycline-resistant early-stage triple-negative breast cancer

Clinton Yam, Elizabeth A. Mittendorf, Haven R. Garber, Ryan Sun, Senthil Damodaran, Rashmi K. Murthy, David L. Ramírez, Meghan Karuturi, Rachel M. Layman, Nuhad K. Ibrahim, Gaiane M. Rauch, Beatriz E. Adrada, Rosalind P. Candelaria, Jason B. White, Elizabeth E. Ravenberg, Alyson R. Clayborn, Qing Qing Ding, W. Fraser Symmans, Sabitha Prabhakaran, Alastair M. Thompson, Vicente Valero, Debu Tripathy, Lei Huo, Stacy L. Moulder, Jennifer K. Litton